Tero
Sign in
Companies›Biotech & health›Rathlin Therapeutics Limited
Download
Company intelligence · Prepared from public filings

Rathlin Therapeutics Limited

ACTIVENo. 14373522Incorporated 23 Sept 2022Londontherapeutics R&D
Register data as of 27 Aug 2026
14 filings read · view all sources ↓
Watch this company
Raised, filed rounds
£25.9m
Priced rounds
3
Peak step-up
–
Peak implied valuation
£34.7m
Last allotment
Jul 2026
Exhibit 1

Implied valuation at each priced allotment, 2023 to 2026

Implied post-money, GBP · price per share beneath each point · from SH01 filings
£9.7m£19.4m£29.2m£38.9m20232024202520261 Sept 2023: £15.2m implied post-money at £0.631 per share17 Mar 2025: £29.8m implied post-money at £0.616 per share14 Jul 2026: £34.7m implied post-money at £0.597 per share£15.2m£0.631/sh£29.8m£0.616/sh£34.7m£0.597/sh
Source: Companies House, forms SH01 filed by Rathlin Therapeutics Limited; Tero analysis. Each point is one filed allotment; click any point to open the underlying filing.
Exhibit 2

Funding rounds, as filed

AllottedShare classPrice / shareRaisedImplied post-moneyStep vs priorSource
14 Jul 2026SERIES A£0.597£5.0m£34.7m· 1.0xSH01 ↗
17 Mar 2025SERIES A£0.616£12.0m£29.8m· 1.0xSH01 ↗
1 Sept 2023SERIES A£0.631£8.9m£15.2mfirstSH01 ↗
Total, 3 priced rounds£25.9m
Source: Companies House filing history, company 14373522. Every row links to the filed document it was read from. Prices and share counts as filed; implied post-money is price per share times shares in issue after the allotment.
Similar companies on the register
Artios Pharma Limited
DNA damage response drug discovery
Grey Wolf Therapeutics Limited
immuno-oncology therapeutics
Draig Therapeutics Ltd
neuroscience therapeutics
Genomics Limited
genomic risk prediction
Methodology
Notes. Raised is the sum of shares allotted times price per share across priced allotments filed on form SH01. Peak step-up is the highest price per share divided by the first priced round. Implied post-money is price per share times shares in issue after the allotment: an approximation that ignores class rights and unexercised options. Allotments classified as option-scheme or nominal issues are excluded from the trajectory.
Primary documents
Every figure on this page is read from a document filed at Companies House and links to it. The full record is public: filing history of Rathlin Therapeutics Limited at Companies House ↗. Tero retains an archived copy of each parsed filing. Information, not investment advice.